Сombined radiotherapy for cervical cancer with the use of polyradiosensitization with cisplatin and gemcitabine - immediate trial results of Azerbaijan national center of oncology

Cover Page


Aim. Study of immediate results of chemoradiotherapy of locally advanced cervical cancer with the use of polyradiosensitization with cisplatin and gemcitabine. Methods. The article analyzes diagnostic and treatment results of 128 patients with IIA-IIIB stage cervical cancer. The age of patients varied between 31 and 76 years. External beam radiotherapy was performed with 1.8 Gy fraction up to a total dose of 45 Gy, high dose rate brachytherapy consisted of four 7.0 Gy fractions. Patients from group 1 received weekly infusions of cisplatin (40 mg/m2) and from group 2 - polyradiosensitization with cisplatin (40 mg/m2) and gemcitabine (75 mg/m2). Results. Chemoradiotherapy with the use of polyradiosensitization compared to standard chemoradiotherapy allowed significant improving of immediate results of treatment of patients with locally advanced cervical cancer, which was particularly prominent in such unfavorable cases as cervical adenocarcinoma and IIIB stage of the disease. Early toxicity of the treatment was higher in group 2 but effectively resolved with symptomatic supportive treatment and did not lead to interruptions in radiotherapy. Conclusion. Combination of conformal external beam radiotherapy, high dose rate intracavitary brachytherapy and concurrent polychemotherapy with cisplatin and gemcitabine is feasible and reasonably safe; chemoradiotherapy with the use of polyradiosensitization improves immediate results of the treatment of cervical cancer with acceptable level of toxicity.

J A Aliyev

Author for correspondence.
National Center of Oncology Baku, Azerbaijan

I H Isayev

National Center of Oncology Baku, Azerbaijan

K S Akbarov

National Center of Oncology Baku, Azerbaijan

E H Guliyev

National Center of Oncology Baku, Azerbaijan

N R Aliyeva

National Center of Oncology Baku, Azerbaijan

N S Aliyeva

National Center of Oncology Baku, Azerbaijan

  • International Agency for Research on Cancer / World Health Organization. Latest world cancer statistics. Press release №223, 12 December 2013. https://www.iarc.fr/en (access date: 13.04.2017).
  • GLOBOCAN 2012: estimated cancer incidence, mortality and prevalenceworldwide in 2012. http://globocan.iarc.fr. (access date: 13.04.2017).
  • Алиев Д.А., Марданлы Ф.А., Гулиев Ф.А. и др. Эпидемиологические аспекты злокачественных новообразований в Азербайджанской Республике за 2008-2013 гг. Азербайджанский ж. онкол. и гематол. 2014; (2): 6-12.
  • Исаев И.Г., Акперов К.С. Перспективы применения таргетных препаратов в лечении рака шейки матки. Азербайджанский ж. онкол. и гематол. 2015; (1): 25-30.
  • Minig L., Patrono M., Romero N. et al. Different strategies of treatment for uterine cervical carcinoma stage IB2-IIIB. World J. Clin. Oncol. 2014; 5 (2): 86-92. doi: 10.5306/wjco.v5.i2.86.
  • Viswanathan A., Beriwal S., Santos J. et al. The American Brachytherapy Society Treatment Recommendations for locally advanced carcinoma of the cervix. Part II: High Dose-Rate Brachytherapy. Brachytherapy. 2012; 14 (1): 47-52. doi: 10.1016/j.brachy.2011.07.002.
  • Hanna T., Delaney G., Barton M. The population benefit of radiotherapy for gynaecological cancer: Local control and survival estimates. Radiotherap. Oncol. 2016; 120 (3): 370-377. doi: 10.1016/j.radonc.2016.04.008.
  • Sturdza A., Pötter R., Fokdal L. Image guided brachytherapy in locally advanced cervical cancer: Improved pelvic control and survival in RetroEMBRACE, a multicenter cohort study. Radiotherap. Oncol. 2016; 120 (3): 428-433. doi: 10.1016/j.radonc.2016.03.011.
  • Шакирова Э.Ж., Муллагалиева А.М., Хасанов Р.Ш., Сухорукова Л.К. Меcтно-распространённый рак шейки матки: проблемы диагностики и лечения. Казанский мед. ж. 2007; 88 (6): 627-630. .
  • Панов А.В., Бурмистров М.В., Рагинов И.С. и др. Опыт использования полирадиомодификации с применением озон-кислородной смеси в комплексном лечении плоскоклеточного рака шейки матки. Казанский мед. ж. 2012; 93 (6): 879-883. .
  • Mountzios G., Soultati A., Pectasides D. et al. Novel approaches for concurrent irradiation inlocally advanced cervical cancer: platinum combinations, non-platinum-containing regimens, and molecular targeted agents. Obstet. Gynecol. Intern. 2013; 2013: 1-8. doi: 10.1155/2013/536765.
  • Duenas-Gonzalez A., Zarba J., Patel F. et al. Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix. J. Clin. Oncol. 2011; 29 (13): 1678-1685. doi: 10.1200/JCO.2009.25.9663.
  • Yahya S., Bhatt L., King M. et al. Survival and toxicity following chemoradiation for carcinoma of the cervix - impact of multiple-phase treatment and shielding. Anticancer Res. 2015; 35 (10): 5567-5574. PMID: 26408727.
  • Therasse P., Arbuck S.G., Eisenhauer E.A. et al. New guidelines to evaluate the response to treatment in solid tumors. J. Natl. Cancer Inst. 2000; 92: 205-216. doi: 10.1093/jnci/92.3.205.
  • Cancer therapy evaluation program, Common Terminology Criteria for Adverse Events v3.0- CTCAE V3.0, DCTD, NCI, NIH, DHHS. http://ctep.cancer.gov (access date: 16.04.2017).


Abstract - 100

PDF (Russian) - 67

© 2017 Aliyev J.A., Isayev I.H., Akbarov K.S., Guliyev E.H., Aliyeva N.R., Aliyeva N.S.

Creative Commons License

This work is licensed
under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Свидетельство о регистрации СМИ ЭЛ № ФС 77-70434 от 20 июля 2017 года выдано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор)